Welcome to our dedicated page for Sharps Tech news (Ticker: STSS), a resource for investors and traders seeking the latest updates and insights on Sharps Tech stock.
Sharps Technology Inc. (NASDAQ: STSS) generates news at the intersection of medical devices, capital markets, and digital assets. Public communications describe the company as a medical device and pharmaceutical packaging business, a medical device sales and distribution platform, and a medical device company with a Solana-focused digital asset treasury strategy. As a result, STSS news covers both healthcare-related operations and developments in its Solana-based treasury model.
News updates for Sharps Technology frequently highlight smart-safety syringe products, medical device distribution activities, and strategic shifts such as the reported exit from legacy syringe manufacturing to streamline operations. At the same time, a significant portion of recent coverage focuses on the company’s Solana digital asset treasury, including acquisitions of SOL funded through private placements and PIPE financings, and the resulting SOL holdings.
Investors following STSS news can expect announcements about treasury strategy execution, such as collaborations with Coinbase Institutional, Crypto.com, Jupiter Exchange, and BONK. These stories often describe how Sharps Technology uses institutional-grade custody, OTC desks, validators, and liquid staking platforms to manage and deploy its SOL holdings, earn staking yields, and support liquidity and security across the Solana ecosystem.
Sharps Technology’s news flow also includes capital markets and corporate actions, including large private placement transactions, warrant-related developments, and a stock repurchase program authorizing the repurchase of up to $100 million of common stock. Readers can use the STSS news page to monitor updates on its Solana validator initiatives, staking partnerships, treasury performance commentary, and ongoing medical device distribution business. For those tracking how a Nasdaq-listed medical device company integrates a blockchain-focused treasury strategy, this news feed provides a consolidated view of Sharps Technology’s public announcements and disclosures.
Sharps Technology (NASDAQ: STSS, STSSW) is hosting an exclusive live investor webinar on June 18, 2024, at 4:15 p.m. ET, featuring CEO Robert Hayes. The event will discuss Sharps' recent $200 million syringe Sales Agreement with Nephron and an Asset Purchase Agreement. The manufacturing plan, starting upon closing the acquisition in 45 days, includes upgrading facilities to produce COC prefillable syringes. The first production line should be ready by early Q2 2025, with all three lines operational by Q4 2025. Sharps is also eyeing sales with Fortune 500 medical distributors and other pharma leaders, aiming for market shipping by early Q2 2025.
Sharps Technology (NASDAQ: STSS, STSSW) has secured a $30 million purchase order from Nephron Pharmaceuticals for their first 12 months of prefillable copolymer syringes. The syringes, available in 10mL and 50mL sizes, will be manufactured at a newly acquired facility in West Columbia, South Carolina. This purchase order is part of a larger five-year, $200 million Syringe Sales Agreement. The new facility, expected to be operational by Q2 2025, aims to exceed $35 million in revenue in its first year, with projections of over $50 million in 2026, and potentially $100 million by 2028. The advanced syringe technology offers significant benefits, including reduced breakage and contamination, and improved cold-chain storage.
Soligenix and Sharps Technology will be featured in interviews on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, airing June 8 at 7 p.m. ET. Soligenix, a late-stage biopharmaceutical company, highlights its promising portfolio, including HyBryte™ for cutaneous T-cell lymphoma, which showed positive Phase 3 results and has a $250 million market potential. It also features SGX302 for psoriasis and SGX203 for pediatric Crohn's disease, targeting markets over $1 billion collectively. Sharps Technology, meanwhile, has secured a $200 million Sales Agreement and acquired Nephron Pharmaceuticals' InjectEZ facility, positioning itself as North America's first dedicated polymer prefillable syringe manufacturer. Projected revenues include $35 million in the first 12 months, with potential growth up to $100 million by 2028.
Sharps Technology has secured exclusive rights to purchase InjectEZ assets with a $1 million escrow deposit. The acquisition includes a five-year, $200 million syringe sales agreement with Nephron Pharmaceuticals. The transaction is expected to close within 60 days, with product shipments slated to begin in Q2 2025. The South Carolina facility will produce pharmaceutical-grade prefillable syringes, with projected revenue exceeding $35 million in the first 12 months. The manufacturing plan includes three phases, with the final phase expected to be completed by October 2027. Sharps is also collaborating with Fortune 500 medical distributors and pharmaceutical companies to expand its market reach.
Sharps Technology (NASDAQ: STSS) has signed an enhanced Asset Purchase Agreement with Nephron Pharmaceuticals to acquire InjectEZ manufacturing assets in South Carolina. The $35 million acquisition includes a five-year, $200 million syringe Sales Agreement, positioning Sharps as the first dedicated polymer prefillable syringe manufacturer in North America. Expected revenues are $35 million in the first 12 months, with potential growth to $100 million by 2028. The facility will start delivering products by Q2 2025. The deal also involves a $9 million and $4.75 million investment for production line expansions, potentially adding $65 million in annual revenue by 2027. This strategic move is fueled by FDA recalls, tariffs, and a shift from glass to polymer syringes.
Sharps Technology has signed a $200 million, 5-year syringe sales agreement with Nephron Pharmaceuticals and an asset purchase agreement (APA) to acquire InjectEZ's syringe manufacturing assets for $35 million. This acquisition, expected to close within 60 days, will establish a dedicated prefillable syringe manufacturing plant in West Columbia, SC. The facility aims to start production by Q2 2025, projecting $37 million in revenue in the first 12 months. This deal expands Sharps' manufacturing capacity in the U.S. and Europe and positions the company for growth in the copolymer prefillable syringe market.
Sharps Technology (NASDAQ: STSS) CEO Robert Hayes addresses shareholders about the impact of recent FDA actions and tariffs. The FDA raised quality concerns over Chinese syringes in November 2023, leading to recalls and warnings in early 2024. The Biden Administration increased tariffs on Chinese syringes from 0% to 50% in May 2024. Sharps Technology, with its high-quality syringe products like SecureGard and SoloGard, is poised to fill the supply gap. The company manufactures in Hungary and plans to add a US facility. Sharps has also formed partnerships with Roncadelle Operations and Owens & Minor to expand market reach and distribution. These steps are expected to drive revenue growth and market presence.
Summary not available.
Summary not available.
Summary not available.